ImmunityBio, Inc. (IBRX)
8.22
-0.09
(-1.08%)
USD |
NASDAQ |
Oct 23, 16:00
8.22
0.00 (0.00%)
Pre-Market: 20:00
ImmunityBio Enterprise Value : 9.529B for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 9.529B |
| October 22, 2026 | 9.624B |
| October 21, 2026 | 9.972B |
| October 20, 2026 | 10.11B |
| October 19, 2026 | 9.740B |
| October 16, 2026 | 10.54B |
| October 15, 2026 | 11.40B |
| October 14, 2026 | 11.31B |
| October 13, 2026 | 11.19B |
| October 12, 2026 | 11.53B |
| October 09, 2026 | 11.94B |
| October 08, 2026 | 11.31B |
| October 07, 2026 | 11.14B |
| October 06, 2026 | 11.08B |
| October 05, 2026 | 11.80B |
| October 02, 2026 | 11.70B |
| October 01, 2026 | 10.65B |
| September 30, 2026 | 10.81B |
| September 29, 2026 | 10.17B |
| September 28, 2026 | 9.845B |
| September 25, 2026 | 9.761B |
| September 24, 2026 | 9.972B |
| September 23, 2026 | 9.961B |
| September 22, 2026 | 10.66B |
| September 21, 2026 | 9.772B |
| Date | Value |
|---|---|
| September 18, 2026 | 9.803B |
| September 17, 2026 | 9.782B |
| September 16, 2026 | 9.203B |
| September 15, 2026 | 9.445B |
| September 14, 2026 | 9.687B |
| September 11, 2026 | 9.203B |
| September 10, 2026 | 9.003B |
| September 09, 2026 | 9.361B |
| September 08, 2026 | 9.603B |
| September 04, 2026 | 9.382B |
| September 03, 2026 | 9.498B |
| September 02, 2026 | 9.245B |
| September 01, 2026 | 9.161B |
| August 31, 2026 | 9.245B |
| August 28, 2026 | 9.350B |
| August 27, 2026 | 9.719B |
| August 26, 2026 | 9.561B |
| August 25, 2026 | 9.498B |
| August 24, 2026 | 8.855B |
| August 21, 2026 | 9.076B |
| August 20, 2026 | 9.129B |
| August 19, 2026 | 9.435B |
| August 18, 2026 | 9.003B |
| August 17, 2026 | 9.213B |
| August 14, 2026 | 8.845B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Moderna, Inc. | 75.99B |
| Sarepta Therapeutics, Inc. | 2.130B |
| Arrowhead Pharmaceuticals, Inc. | 7.963B |
| Oncolytics Biotech, Inc. | 58.94M |
| Sangamo Therapeutics, Inc. | 39.39M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -230.39M |
| Revenue (Quarterly) | 51.24M |
| Total Expenses (Quarterly) | 281.62M |
| EPS Diluted (Quarterly) | -0.2194 |
| Gross Profit Margin (Quarterly) | 90.82% |
| Profit Margin (Quarterly) | -449.6% |
| Earnings Yield | -11.79% |
| Normalized Earnings Yield | -6.623 |